CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 90 enrolled
Drug / intervention
spironolactone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04495712
NCT04495712Phase 4Completed
CompareCT.gov

Antiarrhythmic Effects of Spironolactone in Patients With ICDs

VA Office of Research and Development·interventional·Posted Aug 3, 2020·Updated Oct 9, 2020

In Brief

A Phase 4 clinical trial evaluating spironolactone and placebo for Ventricular Arrhythmias. Completed, enrolled 90 participants across 1 site.

Detailed Summary

This study will test whether spironolactone, an approved drug for among other things hypertension, will reduce the risk of severe arrhythmias in patients with implanted defibrillators. Half the patients in the study will get spironolactone and half will get a placebo. Neither the patients or their providers will know if they are getting spironolactone or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVentricular Arrhythmias
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 3, 2020
Enrollment StartJul 28, 2004
Primary CompletionMay 28, 2008
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.9 years ago

Interventions

spironolactonedrug

aldosterone blocker

placebodrug

identical in appearance to spironolactone study drug